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By far, the majority of studies in molecular evolution have
focused on genetic change across one or more generations.
Much less is known about the genetic changes that occur
during the life time of an individual, or somatic evolution,
of which cancer is probably the best-known example.
Cancer is an adaptive evolutionary process in which dis-
tinct genetic clones compete for space and resources
(Cairns 1975; Greaves and Maley 2012; Nowell 1976).
Modern cancer biology and genomics have validated the
evolutionary nature of cancer, which has attracted much
attention in recent years (Burrell and Swanton 2014; Ger-
linger et al. 2014). Not surprisingly, cancer genomics has
unveiled a significant amount of intratumor heterogeneity
in most tumor types (Burrell et al. 2013; Michor and
Polyak 2010; Swanton 2012). However, but logically, most
studies in cancer genomics have been mostly concerned
with the identification of the genetic and epigenetic chan-
ges that lead to cell transformation, tumor growth, metas-
tasis and drug resistance, and much less with molecular
evolutionary aspects. Despite a relatively rich literature on
cancer evolutionary dynamics (Michor et al. 2004; Sot-
toriva et al. 2011), little is known about the evolutionary
mechanisms that drive tumor progression at the molecular
and cellular level, and evolutionary insights in cancer are
based, for the most part, on mathematical models of car-
cinogenesis (Beerenwinkel et al. 2015).
Fortunately, the chance to obtain a more quantitative
understanding of cancer molecular evolution is here.
Decreasing NGS costs and the already large amount of
genomic data made available by the International Cancer
Genome Consortium (https://dcc.icgc.org) or The Cancer
Genome Atlas (http://cancergenome.nih.gov) should facil-
itate detailed studies on the molecular evolution of cancer.
Still, the paramount opportunity for molecular evolutionary
studies in cancer will be the one provided by single-cell
genomics techniques (Wang and Navin 2015), which open
wide the door for the application of the conceptual and
analytical machinery of molecular evolution. In particular,
population genomics and phylogenomics, which are mostly
based on individualized data (e.g., DNA or protein
sequences), will prove to be critical tools in this regard.
There are multiple fundamental questions in cancer that
might be at least partially answered under a sound
molecular evolution framework. For example, what are the
relative roles of selection and genetic drift? While the
presumption is that selection is the solely driving force in
cancer, this might depend on the particular scenario (Sot-
toriva et al. 2015). In fact, estimates derived from mathe-
matical model fitting suggest that the selective advantage
of driver mutations can be as low as 0.4–1 % (Beeren-
winkel et al. 2007; Bozic et al. 2010). Basic parameters—
such as tumor effective population size, cell generation
times or cell turnover—for understanding the role of
genetic drift in cancer progression have not yet been for-
mally measured (Merlo et al. 2006). Indeed, the charac-
terization of the adaptation process and the role of
neutrality have always been fundamental themes in
molecular evolution (Lachance and Tishkoff 2013; Savo-
lainen et al. 2013), and existing methods should be used to
interrogate cancer genomic data.
In addition, statistical models of evolution will be useful
in testing hypotheses about potentially different substitu-
tion processes acting in a tumor, or to measure tumoral
& David Posada
dposada@uvigo.es
1 Department of Biochemistry, Genetics and Immunology and
Institute of Biomedical Research of Vigo (IBIV), University
of Vigo, 36310 Vigo, Spain
123
J Mol Evol (2015) 81:81–83
DOI 10.1007/s00239-015-9695-7
evolutionary rates from genomic data. Relaxed molecular
clocks could be utilized to estimate whether a metastasis
was established early or late after transformation, or the
temporal dynamics of tumor growth (see for example Zhao
et al. 2014). Also, tumor genealogies could help in
understanding tumor demographics in tempo and space, for
example as typically done in viral epidemiology. Likewise,
models of tumor growth including the cancer stem cell
model (see Navin and Hicks 2010) could be formally
compared under a phylogenetic framework using available
statistical tests. Existing methods for the identification of
convergent evolution might help to pinpoint new ‘‘driver
genes’’, particularly for non-coding regions. Moreover,
ancestral character reconstruction techniques could be
exploited to infer the genomic composition of the initial
cell that originated a primary tumor or a metastasis, and the
order of the different genomic events that took place.
Major evolutionary aspects like the role and extent of
tumor population structure, admixture, or different forms
of gene flow—not just metastases but also the movement of
cells within tumors, or into contiguous regions—currently
not well understood, could also benefit from the use of
standard tools in population genomics.
Indeed, somatic cancer evolution differs from germline
evolution in fundamental ways (Sidow and Spies 2015).
Most importantly, somatic evolution is asexual, proceeding
through cell mitosis and therefore without chromosomal
segregation or crossing over. The fact that the whole cancer
genome is non-recombining implies that genetic hitchhik-
ing and clonal interference should be common (see for
example Neher 2013), but also that the variance of the
different estimates from a single locus will be huge, so
some care is need in this regard. Furthermore, all signifi-
cant variations in cancer occur de novo in each individ-
ual—with the exception of a few transmissible cancers—
meaning that the time scale and the level of divergence will
be very narrow. Importantly, many parameter estimates or
tests in molecular evolution assume neutrality, so the
robustness of these methods to the presence of selection
should be assessed before their application in cancer.
Understanding cancer evolution can have significant
applications, such as more robust predictive biomarkers to
improve personalized treatment and prevent drug resis-
tance (Jamal-Hanjani et al. 2015; McGranahan and
Swanton 2015). Evolutionary signatures such as clonal
expansions or mutational diversity could help predicting
cancer progression (Maley et al. 2006; Mengelbier et al.
2015; see also Neher et al. 2014). Evolutionary biology
concepts and tools remain underused in cancer biology
(Aktipis et al. 2011; Shibata 2012). The availability of
genomic data, in particular that from single cells, should
help change this.
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